Rare Disease Drug Development and Synovial Sarcoma: Why Funding Still Falls Short
A recent BioSpace article highlights a critical challenge in rare disease drug development: many promising therapies are not limited by…
Synovial Sarcoma in Children: A Rare Case Affecting the Lung
Most synovial sarcoma tumors develop in the soft tissues near the joints of the arms or legs in adolescents and…
Synovial Sarcoma Research Pipeline Grows as 15+ Companies Develop New Therapies
Recent industry analyses show that the synovial sarcoma clinical trial pipeline is expanding, with more than 15 companies developing over…
Targeted Therapy Shows Promise in Rare BRAF-Mutated Synovial Sarcoma
Synovial sarcoma is a rare soft tissue sarcoma most commonly treated with surgery, chemotherapy, radiation therapy, and targeted drugs such…
Synovial Sarcoma Treatment Market Growth Reflects Expanding Research
Recent industry analyses suggest the synovial sarcoma treatment market is expected to grow steadily, with projections estimating a compound annual…
A Turning Point for Rare Cancers
What the UK’s Rare Cancers Bill Means for the Synovial Sarcoma Community For decades, patients diagnosed with rare cancers have…
Afamitresgene Autoleucel (Afami-cel): T-Cell Therapy Shows Promise in Synovial Sarcoma
Synovial sarcoma is a rare and often aggressive cancer that can become difficult to treat once it spreads. Traditional chemotherapy…
Synovial Sarcoma Foundation Hosts Second Community Webinar Highlighting Research Momentum
On February 19, 2026, the Synovial Sarcoma Foundation brought together patients, families, clinicians, and researchers from around the world for…
Rethinking the Driver: New Research Identifies P300 as a Critical Co-Factor in Synovial Sarcoma
Synovial sarcoma is driven by a defining genetic event — the SS18-SSX fusion protein, present in nearly all cases. For…